Market Research Report
Cystic Fibrosis - Pipeline Review, H2 2020
|Published by||Global Markets Direct||Product code||232829|
|Published||Content info||550 Pages
Delivery time: 1-2 business days
|Cystic Fibrosis - Pipeline Review, H2 2020|
|Published: October 30, 2020||Content info: 550 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H2 2020, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.
Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body's organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 38, 21, 2, 66, 35 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.
Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.